Gosselies and La Louvière, Belgium. The Mutualité Libérale Namur-Hainaut announces funding for the OncoDNA Company’s genetic profiling test. This initiative is a first in Belgium and a major step towards precision médicine. Each adult member who has a stage 3 or 4 solid tumour cancer and relapses after first-line treatment will receive a partial reimbursement for their tumour analysis known as “OncoDEEP”, amounting to €1,500, or around half of its cost. Discover the official press release here.